Background: Chronic kidney disease (CKD) often results in renal anemia, impacting the well-
being of patients and causing various negative consequences. Erythropoiesis-stimulating …

Abstract Purpose Maintaining target hemoglobin (Hb) with minimal variability is a challenge
in hemodialysis (HD) patients. The aim of this study is to compare the long-and short-acting …

Anemia is one of the most common complications of chronic kidney disease. Treatment of
anemia in Egyptian patients with chronic kidney disease (CKD) and under hemodialysis …

Anemia is the most common side effect in patients with chronic kidney disease (CKD) mainly
due to lower levels of erythropoietin (EPO) hormone. The aim of the present study is to …

Background: Anemia is one of the most common complications of Chronic Kidney Disease
(CKD). The vast majority of Egyptian CKD patients are interchangeably treated with …

Abstract Background/Aims: Erythropoiesis-stimulating agents (ESAs) are effective in the
management of the anaemia of chronic kidney disease but add substantially to the treatment …

Background Erythropoiesis‐stimulating agents (ESAs) are commonly used to treat anaemia
in people with chronic kidney disease (CKD). However, their use has been associated with …

Stage 3 chronic kidney disease (CKD), which is characterized by a glomerular filtration rate
of 30 to 60 mL/min/1.73 m 2 (reference range, 90-200 ml/min/1.73 m 2 for a 20-year-old, with …

This is the protocol for a review and there is no abstract. The objectives are as follows: We
aim to conduct a systematic review and meta-analysis of all RCTs that compare ESAs …

Despite extensive use, to the best of our knowledge, no trial has simultaneously compared
the three currently used erythropoietin‐stimulating agents (ESA s) in a prospective manner …